Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.

Tepotinib shows dose proportionality up to at least the therapeutic dose, and time-independent clearance with a profile appropriate for once-daily dosing. None of the covariates identified had a clinically meaningful effect on tepotinib exposure or required dose adjustments.